MiNK Therapeutics (INKT) Expected to Announce Quarterly Earnings on Thursday

Key Points

• MiNK Therapeutics is expected to announce its Q2 2025 earnings results on Thursday, August 14th, with analysts projecting an earnings loss of ($0.45) per share.
• The company's stock price has decreased by 10.1%, opening at $13.06, after previously reaching a twelve month high of $76.00.
• Recent ratings changes include William Blair downgrading MiNK Therapeutics from "outperform" to "market perform," while B. Riley upgraded the stock to a "strong-buy" rating.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.09). On average, analysts expect MiNK Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MiNK Therapeutics Price Performance

Shares of INKT traded down $0.60 during trading hours on Friday, hitting $12.06. The stock had a trading volume of 175,191 shares, compared to its average volume of 3,033,873. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00. The firm has a market capitalization of $48.12 million, a PE ratio of -4.79 and a beta of 0.33. The stock has a fifty day moving average price of $13.15 and a 200 day moving average price of $9.99.

Wall Street Analysts Forecast Growth

INKT has been the subject of several recent research reports. HC Wainwright lowered MiNK Therapeutics from a "buy" rating to a "neutral" rating and set a $35.00 price target for the company. in a report on Tuesday, July 15th. William Blair lowered MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, July 11th. Finally, B. Riley raised MiNK Therapeutics to a "strong-buy" rating in a report on Friday, July 18th.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.